Cirsium Biosciences

Startup

At Cirsium Biosciences we are growing the next generation of viral vector manufacturing technologies, to enable cheap, safe and equitable access to life saving genetic therapies. Current processes for manufacturing cGMP viral vectors using suspension cells are exceedingly expensive, difficult to scale, and struggle to meet current or future capacity demands. We have developed sustainable, and platformable manufacturing technologies using transient gene expression in whole plants to produce high quality and high potency AAV viral vectors. Our production platform offers unprecedented speed, and scalability at a fraction of the cost of competitor systems. We are a team of passionate plant scientists, vector engineers and translational scientists dedicated to developing the technologies that will allow gene therapies to meet their global potential for all patients.